| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a722744e77c81c5f5cf415087e2ee92b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-14009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2007-10-18^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc13cd675df2cd27c6dd6ff326a617c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_677fd8d03ecf79cf245afcd2cc98f212 |
| publicationDate |
2011-07-07^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011166074-A1 |
| titleOfInvention |
Cln2 treatment of alzheimer's disease |
| abstract |
A method of treating Alzheimer's Disease may include administering to a subject in need of such treatment a CLN2 therapeutic having beta-amyloid degradation activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9399791-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10533208-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10279015-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018521964-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HR-P20171905-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015148120-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016182862-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10758598-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017067028-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9840727-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11229687-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9849195-B2 |
| priorityDate |
2006-10-18^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |